UTHR

Liquidia Corporation has reached a global settlement with United Therapeutics, resolving all six pending legal disputes and ensuring continued access to Yutrepia for PAH patients. However, the company must pay $380.7 million in settlement obligations across 2026-2027, and the removal of the PH-ILD indication from Yutrepia's label narrows its approved use. The company reported preliminary Q3 2026 Yutrepia sales of $222.7 million and plans to advance pipeline candidate L606.

In a comparison of two medical-drugs stocks, Shionogi & Co., Ltd. (SGIOY) emerges as the superior value option compared to United Therapeutics (UTHR). SGIOY holds a Zacks Rank #2 (Buy) with a Value grade of A, featuring a lower forward P/E ratio of 10.68 versus UTHR's 20.59, and a more favorable P/B ratio of 1.34 compared to UTHR's 3.64. UTHR carries a Zacks Rank #3 (Hold) with a Value grade of C.